Abstract
COVID-19 is a disease with vast impact, yet much remains unclear about patient outcomes. Most approaches to risk prediction of COVID-19 focus on binary or tertiary severity outcomes, despite the heterogeneity of the disease. In this work, we identify heterogeneous subtypes of COVID-19 outcomes by considering ‘axes’ of prognosis. We propose two innovative clustering approaches − ‘Layered Axes’ and ‘Prognosis Space’ – to apply on patients’ outcome data. We then show how these clusters can help predict a patient’s deterioration pathway on their hospital admission, using random forest classification. We illustrate this methodology on a cohort from Wuhan in early 2020. We discover interesting subgroups of poor prognosis, particularly within respiratory patients, and predict respiratory subgroup membership with high accuracy. This work could assist clinicians in identifying appropriate treatments at patients’ hospital admission. Moreover, our method could be used to explore subtypes of ‘long COVID’ and other diseases with heterogeneous outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
HW and HZ are supported by a Medical Research Council and Health Data Research UK Grant (MR/S004149/2), an Industrial Strategy Challenge Grant (MC_PC_18029), and a Wellcome Institutional Translation Partnership Award (PIII054). The study was also funded by Legal and General PLC (research grant to establish the independent Advanced Care Research Centre at University of Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal and General PLC. XW is supported by National Natural Science Foundation of China (grant number:81700006). QL is supported by National Key R&D Program (2018YFC1313700), National Natural Science Foundation of China (grant number: 81870064) and the "Gaoyuan" project of Pudong Health and Family Planning Commission (PWYgy2018-06).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Research Ethics Committee of Shanghai Dongfang Hospital.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data pre-processing, machine learning details and all relevant scripts are available at https://github.com/knowlab/covid-subtypes. Details of the cohort are described at https://covid.datahelps.life/. The patient data used in the study will not be available due to inability to fully anonymize in line with ethical requirements. Applications for research access should be sent to TS.
